Cargando…

Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review

Inflammatory Bowel Disease (IBD) comprises a group of disorders, in particular Crohn’s disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation affecting the gastrointestinal tract. The treatment of these conditions is primarily based on anti-inflammatory drugs, although the u...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauro, Rita, Mannino, Federica, Irrera, Natasha, Squadrito, Francesco, Altavilla, Domenica, Squadrito, Giovanni, Pallio, Giovanni, Bitto, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699014/
https://www.ncbi.nlm.nih.gov/pubmed/34944563
http://dx.doi.org/10.3390/biomedicines9121748
_version_ 1784620416060358656
author Lauro, Rita
Mannino, Federica
Irrera, Natasha
Squadrito, Francesco
Altavilla, Domenica
Squadrito, Giovanni
Pallio, Giovanni
Bitto, Alessandra
author_facet Lauro, Rita
Mannino, Federica
Irrera, Natasha
Squadrito, Francesco
Altavilla, Domenica
Squadrito, Giovanni
Pallio, Giovanni
Bitto, Alessandra
author_sort Lauro, Rita
collection PubMed
description Inflammatory Bowel Disease (IBD) comprises a group of disorders, in particular Crohn’s disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation affecting the gastrointestinal tract. The treatment of these conditions is primarily based on anti-inflammatory drugs, although the use of biological drugs with lower side effects quickly increased in the last decade. However, the presence of certain polymorphisms in the population may determine a different outcome in response to therapy, reflecting the heterogeneity of the efficacy in patients. Considering that several studies showed important correlations between genetic polymorphisms and response to biological treatments in IBD patients, this systematic review aims to summarize the pharmacogenetics of biologicals approved for IBD, thus highlighting a possible association between some polymorphisms and drug response. With this purpose, we reviewed PubMed papers published over the past 21 years (2000–2021), using as the search term “drug name and IBD or CD or UC and polymorphisms” to underline the role of pharmacogenetic tests in approaching the disease with a targeted therapy.
format Online
Article
Text
id pubmed-8699014
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86990142021-12-24 Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review Lauro, Rita Mannino, Federica Irrera, Natasha Squadrito, Francesco Altavilla, Domenica Squadrito, Giovanni Pallio, Giovanni Bitto, Alessandra Biomedicines Systematic Review Inflammatory Bowel Disease (IBD) comprises a group of disorders, in particular Crohn’s disease (CD) and ulcerative colitis (UC), characterized by chronic inflammation affecting the gastrointestinal tract. The treatment of these conditions is primarily based on anti-inflammatory drugs, although the use of biological drugs with lower side effects quickly increased in the last decade. However, the presence of certain polymorphisms in the population may determine a different outcome in response to therapy, reflecting the heterogeneity of the efficacy in patients. Considering that several studies showed important correlations between genetic polymorphisms and response to biological treatments in IBD patients, this systematic review aims to summarize the pharmacogenetics of biologicals approved for IBD, thus highlighting a possible association between some polymorphisms and drug response. With this purpose, we reviewed PubMed papers published over the past 21 years (2000–2021), using as the search term “drug name and IBD or CD or UC and polymorphisms” to underline the role of pharmacogenetic tests in approaching the disease with a targeted therapy. MDPI 2021-11-23 /pmc/articles/PMC8699014/ /pubmed/34944563 http://dx.doi.org/10.3390/biomedicines9121748 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Lauro, Rita
Mannino, Federica
Irrera, Natasha
Squadrito, Francesco
Altavilla, Domenica
Squadrito, Giovanni
Pallio, Giovanni
Bitto, Alessandra
Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title_full Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title_fullStr Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title_full_unstemmed Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title_short Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
title_sort pharmacogenetics of biological agents used in inflammatory bowel disease: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699014/
https://www.ncbi.nlm.nih.gov/pubmed/34944563
http://dx.doi.org/10.3390/biomedicines9121748
work_keys_str_mv AT laurorita pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT manninofederica pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT irreranatasha pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT squadritofrancesco pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT altavilladomenica pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT squadritogiovanni pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT palliogiovanni pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview
AT bittoalessandra pharmacogeneticsofbiologicalagentsusedininflammatoryboweldiseaseasystematicreview